India to Maldives: Antihair Export Trade Route

To import Antihair formulations into the Maldives, importers must adhere to the following MFDA requirements:

• Importer Authorization: Importers must be registered as authorized medicine importers with a valid importer's permit from MFDA, in accordance with Medicine Regulation R-46/2014 and R-49/2016. (mfda.gov.mv)

• Adverse Drug Reaction (ADR) Reporting System: Importers are required to establish a system for reporting and handling adverse drug reactions. Evidence of this system must be submitted during the registration process. (mfda.gov.mv)

• Documentation: All documents submitted must be in English and signed or endorsed by the relevant regulatory authorities. Unsigned documents are acceptable only if they can be verified with the issuing authorities. (mfda.gov.mv)

• Product Registration: A comprehensive dossier must be submitted for product registration, including:
• Product Information Sheet (PIS): Structured as per MFDA's prescribed format, covering pharmaceutical form, strength, composition, therapeutic indications, dosage, administration, contraindications, warnings, and adverse reactions.
• Cost and Retail Price Breakdown: Including ex-factory cost, wholesale margin, retail price, currency, applicable taxes, and justification based on comparable markets.
• Certificates of Pharmaceutical Product (CPPs): Issued by WHO-authorized National Regulatory Authorities (NRAs) from at least three countries, demonstrating prior approval.
• Stability Data: Both real-time and accelerated stability data consistent with ICH guidelines.
• Summary of Product Characteristics (SmPC): Following the European Medicines Agency (EMA) format, detailing therapeutic indications, posology, method of administration, pharmacological properties, contraindications, and adverse events.

• Dossier Format: While the MFDA does not explicitly mandate the Common Technical Document (CTD) or electronic CTD (eCTD) format, the submission should be comprehensive and well-organized to facilitate the evaluation process.

• Timelines and Fees: Specific timelines for approval and product registration fees are not detailed in the available information. Importers are advised to consult directly with the MFDA for the most current and detailed information.

• GMP Inspection Requirements: The MFDA may require Good Manufacturing Practice (GMP) certification from the manufacturing facilities. While on-site inspections by the MFDA are not explicitly mentioned, compliance with recognized GMP standards is essential. (mfda.gov.mv)

Indian exporters of Antihair formulations must comply with the following quality and GMP standards to supply the Maldivian market:

• GMP Certification: Manufacturing facilities must adhere to WHO Good Manufacturing Practices (GMP) standards. The MFDA recognizes GMP certifications issued by WHO-authorized NRAs.

• Approved Facilities: Specific information regarding Indian manufacturing facilities currently approved by the MFDA is not publicly available. Exporters should ensure their facilities meet international GMP standards and maintain up-to-date certifications.

• Regulatory Actions: As of October 2024, the MFDA confirmed that none of the Indian medicines flagged for quality concerns had been imported into the Maldives. The authority conducted a comprehensive market assessment and found no batches of the identified products in the Maldivian market. (plus.mv)

Several regulatory developments between 2024 and 2026 have impacted Indian pharmaceutical exports to the Maldives:

• Adoption of Indian Pharmacopoeia: In July 2025, the Maldives and India signed a Memorandum of Understanding (MoU) on pharmacopoeia cooperation. The agreement designates the Indian Pharmacopoeia as the official reference framework for assessing medicines in the Maldives, aiming to strengthen regulatory rigor and broaden access to quality-assured treatments. (psmnews.mv)

• National Medicine Policy: In February 2024, the Maldivian government launched its National Medicine Policy, establishing guidelines to facilitate the importation of quality medications. The policy outlines a six-year strategy to ensure timely access to high-quality medicine without discrimination. A key change is the potential for simplified import procedures for drugs originating from countries recognized by the World Health Organization as having robust drug regulatory systems.

These developments indicate a concerted effort by the Maldivian authorities to streamline pharmaceutical importation processes and enhance the quality assurance of medicines available in the country.

The Maldives' pharmaceutical imports totaled $48.02 million in 2024. While specific data on the market size for antihair formulations is not readily available, the demand for such products is influenced by factors including healthcare spending, disease prevalence, and demographic trends. The Maldives' reliance on imported pharmaceuticals underscores the importance of understanding market dynamics to ensure medicine security. (mnjr.mnu.edu.mv)

Pharmaceutical products classified under HS code 30049011 are subject to a 0% MFN import duty rate in the Maldives. This exemption aligns with the country's policy to facilitate access to essential medicines. Additionally, the Maldives has strengthened inspections at ports handling medicine imports to address quality concerns, ensuring that imported pharmaceuticals meet safety standards.

In 2024, the Maldives imported pharmaceutical products from various countries, including the United States ($1.61 million), Malaysia ($2.03 million), and Thailand ($699.78 thousand). While specific data on India's share of the Maldives' antihair imports is not available, India's significant pharmaceutical manufacturing capacity positions it as a key supplier. The Maldives' heavy dependence on a single country for medicine imports has been identified as a policy concern, highlighting the need for diversification to ensure medicine security. (mnjr.mnu.edu.mv)

India has solidified its position as a global leader in the pharmaceutical industry, particularly in the production of generic medicines. As of 2024, the country supplies 20% of the global demand for generic drugs, including 40% of the United States' generic drug needs and 25% of the United Kingdom's market.

The nation's pharmaceutical sector is supported by a robust manufacturing infrastructure, boasting 752 FDA-approved facilities, 2,050 WHO-GMP-certified plants, and 286 EDQM-approved sites as of 2024. This extensive network ensures high-quality production standards for finished dosage forms, including tablets, capsules, syrups, and injections.

India's cost-effective production capabilities are a significant advantage. The country's pharmaceutical manufacturing market was valued at USD 20.6 billion in 2025 and is projected to reach USD 36.5 billion by 2034, growing at a CAGR of 6.37% from 2026 to 2034. This growth is driven by factors such as cost-effective production, government incentives like the PLI scheme, and rising global demand for affordable medicines.

The combination of a vast manufacturing base, stringent regulatory compliance, and cost advantages makes India a preferred source for Antihair formulations globally.

When comparing Antihair formulation exports from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: India's pharmaceutical manufacturing market was valued at USD 20.6 billion in 2025 and is projected to reach USD 36.5 billion by 2034, growing at a CAGR of 6.37% from 2026 to 2034. This growth is driven by factors such as cost-effective production, government incentives like the PLI scheme, and rising global demand for affordable medicines.

• Quality Perception: India's pharmaceutical sector is supported by a robust manufacturing infrastructure, boasting 752 FDA-approved facilities, 2,050 WHO-GMP-certified plants, and 286 EDQM-approved sites as of 2024. This extensive network ensures high-quality production standards for finished dosage forms, including tablets, capsules, syrups, and injections.

• Regulatory Acceptance in Maldives: India's pharmaceutical exports to over 200 countries, including highly regulated markets, demonstrate its compliance with international standards. This compliance facilitates smoother regulatory acceptance in countries like the Maldives.

• Supply Reliability Track Record: India's pharmaceutical exports have been growing steadily, with a 9% increase in 2024, nearly double the global average. This consistent growth indicates a reliable supply chain.

In contrast, while China offers competitive pricing, concerns about quality and regulatory compliance persist. The EU provides high-quality products but at a higher cost. Local manufacturers in the Maldives may lack the capacity and regulatory approvals to produce Antihair formulations at scale.

India's pharmaceutical industry has demonstrated a strong track record in supply reliability and capacity:

• Manufacturing Capacity: With over 500 active pharmaceutical ingredient (API) producers, India accounts for approximately 8% of the global API market. This extensive capacity supports the production of finished dosage forms, including Antihair formulations.

• Packaging and Cold Chain Capabilities: India's pharmaceutical sector includes numerous facilities equipped with advanced packaging and cold chain logistics, ensuring the integrity of temperature-sensitive formulations.

• Regulatory Compliance Track Record: Compliance has improved significantly, with US FDA Official Action Indicated (OAI) instances dropping by 50% in the last decade and European Medicines Agency (EMA) non-compliance cases falling by 27%.

• Capacity Constraints or Expansion Plans: The Indian pharmaceutical industry is projected to achieve a turnover of USD 130 billion by 2030, indicating ongoing expansion and capacity enhancement.

These factors collectively ensure a reliable supply chain for Antihair formulations from India to the Maldives.

For Maldivian buyers sourcing Antihair formulations from India, the following strategic recommendations are advised:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Antihair formulations.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Establish clear payment terms, such as letters of credit or advance payments, to build trust and ensure timely deliveries.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet international quality standards.

• Regulatory Compliance: Verify that the selected suppliers have the necessary regulatory approvals and certifications required for importation into the Maldives.

Implementing these strategies will enhance the efficiency and reliability of sourcing Antihair formulations from India.

By adhering to these guidelines, Maldives companies can establish reliable partnerships with Indian Antihair formulation suppliers, ensuring the delivery of safe and effective pharmaceutical products to the market.